Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Bloom has pioneered a technology to transform plant waste into valuable chemical products
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Subscribe To Our Newsletter & Stay Updated
